US04216R1023 - Common Stock
ARMATA PHARMACEUTICALS INC
NYSEARCA:ARMP (5/3/2024, 7:04:00 PM)
2.49
0 (0%)
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
ARMATA PHARMACEUTICALS INC
5005 Mcconnell Ave
Los Angeles CALIFORNIA 90292
P: 13106652928
CEO: Todd R. Patrick
Employees: 72
Website: https://www.armatapharma.com/
ARMP stock results show that Armata Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, Armata Pharmaceuticals (ARMP) enters...
It's time to start the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday!
Here you can normally see the latest stock twits on ARMP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: